[1]姚俊波,贾 波,刘加元,等.前列腺癌患者血清TWEAK 和SREBP-1 水平表达与临床病理特征及无进展生存预后的关系研究[J].现代检验医学杂志,2024,39(03):136-141.[doi:10.3969/j.issn.1671-7414.2024.05.023]
　YAO Junbo,JIA Bo,LIU Jiayuan,et al.Study on the Serum TWEAK and SREBP-1 Levels in Patients with Prostate Cancer and Their Relationship with Clinical Pathological Characteristics and Progression Free Survival Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(03):136-141.[doi:10.3969/j.issn.1671-7414.2024.05.023]
点击复制

前列腺癌患者血清TWEAK 和SREBP-1 水平表达与临床病理特征及无进展生存预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
136-141
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Study on the Serum TWEAK and SREBP-1 Levels in Patients with Prostate Cancer and Their Relationship with Clinical Pathological Characteristics and Progression Free Survival Prognosis
文章编号:
1671-7414（2024）05-136-06
作者:
姚俊波; 贾 波; 刘加元; 邹一鸣; 邓思文
（武汉市东西湖区人民医院泌尿外科，武汉 430040）
Author(s):
YAO Junbo;  JIA Bo;  LIU Jiayuan;  ZOU Yiming;  DENG Siwen
（Department of Urology, Wuhan Dongxihu District People’s Hospital，Wuhan 430040, China）
关键词:
前列腺癌; 肿瘤坏死因子样弱凋亡诱导因子; 固醇调控元件结合蛋白-1
分类号:
R737.25；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.05.023
文献标志码:
A
摘要:
目的 研究前列腺癌（prostate cancer，PC）患者血清肿瘤坏死因子样弱凋亡诱导因子(tumor necrosis factorlike weak inducer of apoptosis，TWEAK)、固醇调节元件结合蛋白1(sterol regulatory element-binding protein 1，SREBP-1)表达与临床病理特征及无进展生存预后的关系。方法 选取2018 年1 月～ 2020 年1 月武汉市东西湖区人民医院行PC根治术的94 例PC 患者为PC 组，以同期50 例前列腺增生（benign prostatic hyperplasia，BPH）患者为BPH 组，以同期体检的50 例健康人为对照组。酶联免疫吸附试验 (enzyme-linked immunosorbent assay，ELISA) 检测血清TWEAK 和SREBP-1 表达水平。Kaplan-Meier 生存分析比较血清TWEAK 和SREBP-1 对PC 患者无进展生存预后的影响。多因素COX回归分析影响PC患者无进展生存预后的因素。结果 PC组患者血清TWEAK（77.14 ± 15.46 ng/L），SREBP-1（334.14± 33.81 ng/L） 高于BPH 组（38.69 ± 10.58 ng/L，201.69 ± 28.74 ng/L） 和对照组（36.26 ± 10.27 ng/L，189.51 ±27.65 ng/L），差异具有统计学意义（t=23.752，25.249；34.636，37.821，均P ＜ 0.05）。PC 患者血清TWEAK 与SREBP-1 表达呈显著正相关（r=0.668，P=0.001）。Gleason 评分＞ 7 分、TNM 分期Ⅲ期及术前前列腺特异抗原（prostatespecific antigen，PSA）水平≥ 20 ng/ml 的PC 患者血清TWEAK，SREBP-1 水平高于Gleason 评分≤ 7 分，TNM分期Ⅰ～Ⅱ期及术前PSA 水平＜ 20 ng/ml，差异具有统计学意义(t=8.465 ～ 16.597，均P<0.05)。TWEAK 高表达组和低表达组三年总体无进展生存率分别为60.42%（29/48）和86.96%（40/46），SREBP-1 高表达组和低表达组三年总体无进展生存率分别为57.78%（26/45）和87.76%（43/49）；TWEAK 高表达组、SREBP-1 高表达组三年累积无进展生存率低于TWEAK 低表达组、SREBP-1 低表达组，差异具有统计学意义（Log-rank χ2=8.125，9.547，P=0.004，0.002）。TNM 分期Ⅲ期（OR=1.448，P ＜ 0.001）、Gleason 评分＞ 7 分（OR=1.401，P ＜ 0.001）、术前PSA ≥ 20 ng/ml（OR=1.353，P ＜ 0.001）及血清TWEAK（OR=1.338，P ＜ 0.001）和SREBP-1（OR=1.293，P ＜ 0.001）是影响PC 患者无进展生存预后的独立危险因素。结论 PC 患者血清TWEAK 和SREBP-1 升高，两者与PC 临床病理特征相关，是评估无进展生存预后的血清标志物。
Abstract:
Objective To investigate the serum tumor necrosis factor like weak inducer of apoptosis(TWEAK)，sterol regulatory element-binding protein 1(SREBP-1) levels in patients with prostate cancer (PC) and their relationship with clinical pathological characteristics and progression free survival prognosis. Method A total of 94 PC patients who underwent PC radical surgery in Wuhan Dongxihu District People’s Hospital from January 2018 to January 2020 were selected as the PC group. Meanwhile, 50 patients with benign prostatic hyperplasia (BPH) during the same period were selected as the BPH group, and 50 healthy individuals who underwent physical examination during the same period were selected as the control group. Enzyme linked immunosorbent assay（ELISA）was used to detect the expression levels of serum TWEAK and SREBP-1. Kaplan-Meier survival analysis was used to analyze the effects of serum TWEAK and SREBP-1 on the progression free survival in prostate cancer patients. Multivariate COX regression analysis was used to analyze factors affecting the prognosis of progression free survival in prostate cancer patients. Results The serum TWEAK (77.14 ± 15.46 ng/L) and SREBP-1 (334.14 ± 33.81 ng/L) levels in the PC group were higher than those in the BPH group（38.69 ± 10.58 ng/L，201.69 ± 28.74 ng/L）and control group（36.26 ± 10.27 ng/L，189.51 ± 27.65 ng/L）, with significant differences (t=23.752, 25.249; 34.636, 37.821, all P<0.05). There was a positive correlation between serum TWEAK and SREBP-1 expression in PC patients (r=0.668, P=0.001). The serum TWEAK and SREBP-1 levels in PC patients with Gleason score>7, TNM stage III, and preoperative prostate specific antigen (PSA) level ≥ 20 ng/ml were higher than those with Gleason score ≤ 7, TNM stage I ～ II, and preoperative PSA level < 20ng/ml, with significance differences (t=8.465 ～ 16.597, all P<0.05). The 3-year overall progression free survival rates of the TWEAK high expression and low expression groups were 60.42% (29/48) and 86.96% (40/46), respectively. The 3-year overall progression free survival rates of the SREBP-1 high expression and low expression groups were 57.78% (26/45) and 87.76% (43/49), respectively. The 3-year cumulative progression free survival rates of the TWEAK high expression group and the SREBP-1 high expression group were lower than those of the TWEAK low expression group and the SREBP-1 low expression group, and the differences were significant (Log rank χ2=8.125, 9.547, P=0.004, 0.002). TNM stage III (OR=1.448, P<0.001), Gleason score > 7 (OR=1.401, P<0.001), preoperative PSA ≥ 20 ng/ml (OR=1.353, P<0.001), serum TWEAK (OR=1.338, P<0.001), and SREBP-1 (OR=1.293, P<0.001) were independent risk factors affecting the progression free survival prognosis of PC patients. Conclusion Serum TWEAK and SREBP-1 in prostate cancer patients were increased, and they were correlated with the clinical pathological characteristics of PC. They could be serum biomarkers for evaluating the prognosis of progression free survival.

参考文献/References:

[1] BERGENGREN O, PEKALA K R, MATSOUKAS K,et al. 2022 update on prostate cancer epidemiology and risk factors-A systematic review[J]. European Urology,2023, 84(2): 191-206.
[2] CHENG Qing, BUTLER W, ZHOU Yinglu, et al. Preexisting castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy[J]. European Urology, 2022, 81(5): 446-455.
[3] GUPTA R K, GRACIAS D T, FIGUEROA D S,et al. TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy[J]. Science Immunology, 2021, 6(65):eabi8823.
[4] DWYER B J, JARMAN E J, GOGOI-TIWARI J, et al. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression[J]. Journal of Hepatology, 2021, 74(4): 860-872.
[5] CHEN Hao, QI Qinqin, WU Nan, et al. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer[J]. Redox Biology,2022, 55: 102426.
[6] 张训男, 彭春艳, 李显东, 等. 冠心病并发高血压患者外周血白细胞SREBP-1 mRNA 表达水平与脂质代谢紊乱的关系研究[J]. 现代检验医学杂志, 2021,36(5): 1-7. ZHANG Xunnan, PENG Chunyan, LI Xiandong,et al. Correlation analysis between leukocytes SREBP-1 mRNA expression and serum lipids level in hypertensive patients with coronary artery disease[J].Journal of Modern Laboratory Medicine, 2021, 36(5):1-7.
[7] CHENG Chunming, GENG Feng, LI Zoe, et al. Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth[J]. Nature Metabolism, 2022, 4(5): 575-588.
[8] 李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J].肿瘤防治研究, 2021, 48(1): 98-102. LI Xing, ZENG Xiaoyong. Advances in epidemiology of prostate cancer in China[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 98-102.
[9] CARLSSON S V, VICKERS A J. Screening for prostate cancer[J]. Medical Clinics of North America, 2020,104(6), 1051-1062.
[10] ALTUNA-COY A, RUIZ-PLAZAS X, ALVESSANTIAGO M, et al. Serum levels of the cytokine TWEAK are associated with metabolic status in patients with prostate cancer and modulate cancer cell lipid metabolism in vitro[J]. Cancers, 2021, 13(18):4688.
[11] LIU Wenting, GAO Lu, HOU Xiaojuan, et al. TWEAK signaling-induced ID1 expression drives malignant transformation of hepatic progenitor cells during hepatocarcinogenesis[J]. Advanced Science (Weinheim Baden Wurttemberg, Germany), 2023, 10(18):e2300350.
[12] KHAN P, EBENEZER N S, SIDDIQUI J A, et al. MicroRNA-1: diverse role of a small player in multiple cancers[J]. Seminars in Cell Developmental Biology,2021, 124: 114-126.
[13] QI Xuefeng, LI Zhen, LI Huan, et al. MicroRNA-1 negatively regulates peripheral NK cell function via tumor necrosis factor-like weak inducer of apoptosis (TWEAK) signaling pathways during PPRV infection[J]. Frontiers in Immunology, 2019, 10: 3066.
[14] ZHOU Ting, ZHANG Lin, LIU Tingting, et al. Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer[J]. Annals of Translational Medicine, 2020, 8(23): 1589.
[15] HOLMBERG R, ROBINSON M, GILBERT S F, et al. TWEAK-Fn14-RelB signaling cascade promotes stem cell-like features that contribute to post-chemotherapy ovarian cancer relapse[J]. Molecular Cancer Research,2023, 21(2): 170-186.
[16] ZAITSEVA O, HOFFMANN A, OTTO C, et al. Targeting fibroblast growth factor (FGF)-inducible 14(Fn14) for tumor therapy[J]. Frontiers in Pharmacology,2022, 13: 935086.
[17] PHAM D V, PARK P H. Adiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 9.
[18] SHORNING B Y, DASS M S, SMALLEY M J, et al. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling[J].International Journal of Molecular Sciences, 2020,21(12): 4507.
[19] KANAGASABAI T, LI Guoliang, SHEN Tianhuai, et al. MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway[J]. Cancer Letters, 2022,525: 46-54.
[20] ZHANG Zhengliang, WANG Weixi, KONG Piaoping,et al. New insights into lipid metabolism and prostate cancer(Review)[J]. International Journal of Oncology,2023, 62(6): 74-85.

相似文献/References:

[1]廖洪利,米叶赛尔·阿不都拉.粘着斑激酶在前列腺癌中表达的研究[J].现代检验医学杂志,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
　LIAO Hong-li,MIYESAIER·Abdula.Research on Expression of FAK in Prostate Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(03):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
[2]范维肖,刁艳君,马越云,等.超速离心法与QIAGEN膜亲和柱法提取前列腺癌细胞培养上清外泌体的方法学比较[J].现代检验医学杂志,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
　FAN Wei-xiao,DIAO Yan-jun,MA Yue-yun,et al.Comparison of Ultracentrifugation and Membrane Based-Affinity ColumnMethods in Exosome Isolation from Supernatants of Prostate Cancer Cells[J].Journal of Modern Laboratory Medicine,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
[3]潘良明,沈菲菲,马晓英,等.血清前列腺健康指数对 tPSA灰区前列腺癌患者的诊断价值探讨[J].现代检验医学杂志,2021,36(01):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
　PAN Liang-ming,SHEN Fei-fei,MA Xiao-ying,et al.Diagnostic Value of Serum Prostate Health Index in Prostate Cancer Patients with PSA Gray Area[J].Journal of Modern Laboratory Medicine,2021,36(03):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
[4]何　跃,梁　晶,文礼红,等.前列腺癌患者血清IL-17和IL-35水平表达与临床病理特征以及预后的关系研究[J].现代检验医学杂志,2021,36(04):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
　HE Yue,LIANG Jing,WEN Li-hong,et al.Study on the Relationship between Serum IL-17, IL-35 Levels andClinicopathological Features and Prognosis in Patients with Prostate Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
[5]荣　蓉a,古　颖a,高　翔a,等.前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究[J].现代检验医学杂志,2021,36(06):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
　RONG Rong,GU Ying,GAO Xiang,et al.Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(03):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
[6]张士保,朱斐煜,谢瑞玉,等.CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究[J].现代检验医学杂志,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
　ZHANG Shi-bao,ZHU Fei-yu,XIE Rui-yu,et al.Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis[J].Journal of Modern Laboratory Medicine,2022,37(03):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
[7]阴铭迪,李 林.前列腺癌实验室诊断的最新进展[J].现代检验医学杂志,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
　YIN Ming-di,LI Lin.Recent Advances in Laboratory Diagnosis of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
[8]郑江婷,寸淑娥,尹 冶,等.长链非编码RNA 在前列腺癌治疗抵抗中作用机制的研究进展[J].现代检验医学杂志,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
　ZHENG Jiang-ting,CUN Shu-e,YIN Ye,et al.Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2023,38(03):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
[9]孙 飞,黎春明.基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J].现代检验医学杂志,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
　SUN Fei,LI Chun-ming.Prediction of Immunotherapy Effect and Prognosis of Prostate Cancer Based on Immune Cell Tissue Infiltration Immune Score Model[J].Journal of Modern Laboratory Medicine,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
[10]张 珑,李月峰,吴 涛,等.前列腺癌患者血清miR-138-5p，miR-212-5p 水平表达及与临床预后价值[J].现代检验医学杂志,2024,39(05):30.[doi:10.3969/j.issn.1671-7414.2024.05.006]
　ZHANG Long,LI Yuefeng,WU Tao,et al.Expression of Serum miR-138-5p and miR-212-5p Levels and Clinical Prognosis Value in Prostate Cancer[J].Journal of Modern Laboratory Medicine,2024,39(03):30.[doi:10.3969/j.issn.1671-7414.2024.05.006]

备注/Memo

备注/Memo:
基金课题： 湖北省卫生健康委科研项目（WJ2019F064）：血清炎性标志物与前列腺癌预后的关系研究；武汉市医学科研项目（编号：WZ20B03）：中药提取物对男性更年期综合征模型大鼠的疗效筛选及机制研究。
作者简介：姚俊波（1981-），男 ，硕士研究生，主治医师，研究方向：泌尿系结石 ，E-mail: yaojunbo5486@126.com。
通讯作者：贾波（1981-），男， 硕士，副主任医师，研究方向： 泌尿系肿瘤，E-mail: 21079229@qq.com。
更新日期/Last Update: 2024-05-15